Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 10.24 USD -7.25% Market Closed
Market Cap: 432.1m USD
Have any thoughts about
Urogen Pharma Ltd?
Write Note

P/FCFE
Price to FCFE

-6
Current
-6.7
Median
23.9
Industry
Higher than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-6
=
Market Cap
432m USD
/
FCFE
-71.9m USD
All Countries
Close
Market Cap P/FCFE
IL
Urogen Pharma Ltd
NASDAQ:URGN
432m USD -6
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 281 532.7
US
Abbvie Inc
NYSE:ABBV
309.5B USD 12.4
US
Amgen Inc
NASDAQ:AMGN
140.9B USD 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
112B USD 11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.6B USD -79.8
US
Epizyme Inc
F:EPE
94.1B EUR -418.2
AU
CSL Ltd
ASX:CSL
137.8B AUD 77
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.7B USD 23.1
US
Seagen Inc
F:SGT
39.3B EUR -57.5
NL
argenx SE
XBRU:ARGX
38.5B EUR -119.3
 
IL
Urogen Pharma Ltd
NASDAQ:URGN
Average P/FCFE: 29.5
Negative Multiple: -6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 281 532.7
US
Abbvie Inc
NYSE:ABBV
12.4
US
Amgen Inc
NASDAQ:AMGN
23.8
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -79.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -418.2
AU
CSL Ltd
ASX:CSL
77
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
23.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -119.3

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A